TITLE:
Long Term Benefit of Autologous Bone Marrow Stem Cell Transplantation without Immunosuppression in Chronic Type 1 Diabetic Patients
AUTHORS:
Alejandro Mesples, Yun Zhang, Xiang Hu
KEYWORDS:
Type 1 Diabetes, Bone Marrow Transplantation, Bone Marrow Stem Cells
JOURNAL NAME:
Stem Cell Discovery,
Vol.10 No.1,
January
30,
2020
ABSTRACT: Background:Autologous bone marrow stem cell transplantation
without immune suppression has been proposed as a safe and efficient therapeutic option to replace β-cell
mass destroyed by specific antibodies in chronic type 1 diabetes but we have
not scientific information about how long the metabolic stability is
maintained. Material and Method: From 2010 to 2014, were included 134 chronic type 1
diabetics patients (p.) in an autologous bone marrow stem cell transplantation
protocol, stimulated with filgrastim, without immune suppression, c peptide
Results:C peptide, 6 months after transplantation more than 0.9 ng/ml in 61
patients (45%) (P = 0.001, CI = 95%). At 12 months 50 patients (37%) (P =
0.001, CI = 95%). At 24 months 53 patients (39%) (P = 0.001, CI = 95%). At 36
months 51 patients (38%) (P = 0.001, CI = 95%). A1C before transplant, Conclusion:Autologous bone marrow stem cell transplantation, without immunosuppression,
improves pancreatic function and metabolic control without new immune reaction
after three years of follow up in chronic type 1 diabetic patients.